Source: European Medicines Agency (EU) Revision Year: 2026 Publisher: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Inluriyo 200 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). White, capsule shaped film-coated tablet of 14.0 x 7.5 mm, debossed with "LILLY" on one side and "1717" and an elongated 4-point starburst on the other side. |
Each film-coated tablet contains imlunestrant tosylate equivalent to 200 mg imlunestrant.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Imlunestrant is an antagonist and degrader of wild-type and mutant oestrogen receptor-α (ERα), leading to inhibition of oestrogen receptor-dependent gene transcription and cellular proliferation in ER-positive breast cancer cells. |
| List of Excipients |
|---|
|
Tablet core: Croscarmellose sodium (E468) Film-coating: Macrogols (E1521) |
Polychlorotrifluoroethylene (PCTFE)/Polyvinylchloride (PVC) blister sealed with aluminium foil in packs of 14, 28, 42, 56, 70 or 168 film-coated tablets.
Not all pack sizes may be marketed.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
EU/1/25/2003/001
EU/1/25/2003/002
EU/1/25/2003/003
EU/1/25/2003/004
EU/1/25/2003/005
EU/1/25/2003/006
| Drug | Countries | |
|---|---|---|
| INLURIYO | Austria, Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.